Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Magrolimab + azacitidine in MDS and AML

David Sallman, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, reviews the toleratbility and efficacy data reported from the phase 1b study of magrolimab, an anti-CD47 antibody, in combination with azacitidine in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).